NGS-Based RNA-Sequencing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031F

Nanopore Sequencing is the fastest growing sector, North America is the largest market

The Global NGS-Based RNA-Sequencing Market is projected to expand from USD 3.18 Billion in 2025 to USD 4.75 Billion by 2031, reflecting a compound annual growth rate of 6.92%. This high-throughput genomic technology is utilized to examine the transcriptome, facilitating precise gene expression quantification and the identification of new RNA variants. The market is primarily propelled by the shift toward personalized medicine and the urgent requirement for transcriptomic data in drug discovery, specifically for rare diseases and oncology. This demand is intensified by the creation of advanced therapeutics necessitating strict genomic validation; for instance, the Pharmaceutical Research and Manufacturers of America reported in 2024 that the industry pipeline contained 289 novel cell and gene therapies, highlighting the sector's increasing reliance on sophisticated sequencing tools.

Despite these growth drivers, the market encounters a significant obstacle regarding bioinformatics analysis and data management. The immense datasets produced by modern sequencing platforms demand extensive computational infrastructure and specialized expertise for accurate interpretation. This computational bottleneck frequently delays time-to-result and raises operational expenses, which can hinder broader implementation in clinical environments where streamlined and rapid diagnostics are crucial.

Market Drivers

A primary catalyst for growth is the surging demand for single-cell RNA sequencing, as researchers increasingly require granular resolution to comprehend cellular heterogeneity. Unlike bulk sequencing, which averages gene expression across a sample, single-cell platforms enable the distinct profiling of individual cells, a capability vital for mapping complex tissue microenvironments in immunology and oncology. This technological shift is reflected in the financial performance of specialized providers; according to 10x Genomics' 'Full Year 2023 Financial Results' in February 2024, the company achieved $618.7 million in revenue, a 20% increase from the prior year, largely driven by the adoption of their spatial and single-cell transcriptomics solutions. This trajectory suggests a fundamental move in experimental design toward high-resolution modalities that offer deeper biological insights.

Market expansion is further sustained by growing investments and funding for genomic research, which provide the necessary capital for infrastructure upgrades and large-scale transcriptomics initiatives. Both public and private entities are directing substantial resources toward establishing advanced data centers and sequencing facilities to speed up drug discovery pipelines. For example, the Novo Nordisk Foundation announced in March 2024, via the 'Gefion: New AI supercomputer in Denmark' release, a commitment of approximately DKK 600 million to build a supercomputer tailored for handling massive genomic datasets. This financial support lowers entry barriers for institutions adopting next-generation sequencing workflows and correlates with high-throughput instrument uptake; Illumina's 'Fourth Quarter and Fiscal Year 2023 Results' in February 2024 confirmed the shipment of 352 NovaSeq X instruments, underscoring the global physical expansion of sequencing capacity.

Market Challenges

The Global NGS-Based RNA-Sequencing Market faces a major hurdle concerning data management and bioinformatics analysis. As sequencing technologies yield exponentially larger datasets, the ability to efficiently store, process, and interpret this information has lagged, resulting in a severe computational bottleneck. This disparity complicates workflows and significantly increases operational costs, often prolonging the time needed to extract actionable insights from raw transcriptomic data. Consequently, the complexity of managing these massive datasets restricts the scalability of RNA sequencing within routine clinical diagnostics, where rapid turnaround times are essential for patient care.

This operational inefficiency directly impacts the market's capacity to support precision medicine and drug discovery. According to the Pistoia Alliance in 2024, 52% of life science R&D professionals identified poorly curated and low-quality datasets as the primary barrier to the effective deployment of advanced analytical tools. This statistic highlights a critical gap in data readiness that hampers the industry's ability to utilize genomic data for rigorous validation. Without streamlined bioinformatics infrastructures, the translation of transcriptomic discoveries into therapeutic applications remains inefficient, thereby limiting the broader expansion of the market.

Market Trends

The integration of Machine Learning (ML) and Artificial Intelligence (AI) is fundamentally transforming transcriptomic data interpretation by addressing the critical bioinformatics bottleneck in high-throughput workflows. By using advanced algorithms, researchers can rapidly deconvolve massive datasets to identify actionable biomarkers and predict therapeutic responses efficiently. This technological synergy is driving market adoption as diagnostic providers embed these tools into core offerings to enhance precision medicine capabilities; according to Tempus AI's 'Fourth Quarter and Full Year 2024 Results' report in February 2025, the company recorded a 30.4% year-over-year revenue increase to $693.4 million, attributed to the expansion of its AI-enabled genomics platform.

Simultaneously, the commercialization of third-generation direct RNA sequencing is facilitating the detection of native RNA modifications without cDNA conversion bias. These long-read platforms allow for real-time analysis of full-length transcripts, revealing methylation patterns and splice variants that short-read technologies often miss. This capability is expanding into clinical markets, validating the utility of direct sequencing for complex biological applications. As per Oxford Nanopore Technologies' 'Annual Results for the Year Ended 31 December 2024' announcement in March 2025, the company achieved 11% revenue growth at constant currency, driven notably by a 12% expansion in its Clinical segment.

Key Market Players

• Illumina Inc.
• Thermo Fischer Scientific Inc.
• Oxford Nanopore Technologies plc
• Agilent Technologies, Inc.
• PerkinElmer Inc
• QIAGEN N.V.
• Eurofins Scientific SE
• F. Hoffmann-La Roche Ltd
• Takara Bio Inc.
• Azenta Life Sciences

Report Scope

In this report, the Global NGS-Based RNA-Sequencing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

NGS-Based RNA-Sequencing Market, by Product and Services:

• RNA Sequencing Platforms and Consumables
• Sample Preparation Products
• RNA Sequencing Services
• Data Analysis
• Storage
• Management

NGS-Based RNA-Sequencing Market, by Technology:

• Sequencing By Synthesis
• Ion Semiconductor Sequencing
• Single-Molecule Real-Time Sequencing
• Nanopore Sequencing

NGS-Based RNA-Sequencing Market, by Application:

• Expression Profiling Analysis
• Small RNA Sequencing
• De Novo Transcriptome Assembly
• Variant Calling
• Transcriptome Epigenetics

NGS-Based RNA-Sequencing Market, by End User:

• Research and Academia
• Hospitals and Clinics
• Pharmaceutical and Biotechnology Companies
• Others

NGS-Based RNA-Sequencing Market, by Region:

• North America
• Europe
• Asia Pacific
• South America
• Middle East & Africa

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global NGS-Based RNA-Sequencing Market.

Available Customizations:

With the given market data, the publisher offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

This product will be delivered within 1-3 business days.